Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 291 participants.

Also called NCT02226003

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 291 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02226003
  • EudraCT 2014-001049-25
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02226003. Randomized; double masking; primary purpose treatment. Start 2014-09-23 (actual); primary completion 2016-02-23 (actual). Results posted on 2017-04-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Ertugliflozin
Intervention (Drug)
Sitagliptin
Intervention (Drug)
Placebo to Ertugliflozin
Intervention (Drug)
Placebo to Sitagliptin
Intervention (Drug)
Glimepiride
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)
Collaborator
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct02226003
Content hash
2fe9e550d64165a49e317fcb4c4032c46ab03e92384b4e28695265aa416be4dc